Type 3 innate lymphoid cells dominate the ILC compartment in endstage lung disease

Category	Detail
Condition
Key Mechanisms	Type 3 ILCs dominate and contribute to pro-inflammatory cytokine milieu, particularly IL-17A.
Target Population
Care Setting

Type 3 ILCs are predominant in lung and LN tissues of endstage lung disease patients.
Type 2 ILCs are increased in peripheral blood of clinically stable CF patients.
ILC-derived cytokines contribute to chronic inflammation and tissue remodeling.
Differences in ILC composition persist despite treatment with CFTR modulators.
Study involved analysis of 58 lung donors and 107 lung transplant recipients.
Sustained changes in ILC composition observed even after 24 months of treatment.

Characterization of ILCs in lung and LN tissues for understanding endstage lung disease using flow cytometry and cytokine profiling.

Consideration of ILC composition in treatment strategies for chronic lung diseases.

Longitudinal assessment of ILC populations every 3-6 months in response to treatment.

Persistent alterations in ILC composition may reflect underlying pathological processes.

Changes in ILC composition observed even after 24 months of treatment, indicating potential implications for treatment efficacy.

Monitor ILC populations in patients with chronic lung diseases at regular intervals.
Evaluate the impact of ILC-derived cytokines on treatment outcomes.

Clinical Scorecard: Type 3 Innate Lymphoid Cells Predominate in the ILC Population of Advanced Lung Disease